O	0	15	Immunoglobulins	Immunoglobulin	NNS	B-NP
O	16	26	associated	associate	VBN	B-VP
O	27	31	with	with	IN	B-PP
O	32	40	elevated	elevated	JJ	B-NP
O	41	51	riboflavin	riboflavin	NN	I-NP
O	52	59	binding	binding	NN	I-NP
O	60	62	by	by	IN	B-PP
B-Organism_substance	63	69	plasma	plasma	NN	B-NP
O	70	74	from	from	IN	B-PP
B-Cancer	75	81	cancer	cancer	NN	B-NP
O	82	90	patients	patient	NNS	I-NP
O	90	91	.	.	.	O

B-Organism_substance	92	98	Plasma	Plasma	NN	B-NP
O	99	103	from	from	IN	B-PP
O	104	107	182	182	CD	B-NP
O	108	116	patients	patient	NNS	I-NP
O	117	121	with	with	IN	B-PP
O	122	131	different	different	JJ	B-NP
B-Cancer	132	141	malignant	malignant	JJ	I-NP
I-Cancer	142	150	diseases	disease	NNS	I-NP
O	151	154	was	be	VBD	B-VP
O	155	161	tested	test	VBN	I-VP
O	162	165	for	for	IN	B-PP
O	166	176	riboflavin	riboflavin	NN	B-NP
O	177	184	binding	binding	NN	I-NP
O	185	187	by	by	IN	B-PP
O	188	203	immunoglobulins	immunoglobulin	NNS	B-NP
O	203	204	,	,	,	O
O	205	210	which	which	WDT	B-NP
O	211	215	have	have	VBP	B-VP
O	216	220	been	be	VBN	I-VP
O	221	229	recently	recently	RB	I-VP
O	230	240	identified	identify	VBN	I-VP
O	241	243	as	as	IN	B-PP
O	244	249	major	major	JJ	B-NP
O	250	258	carriers	carrier	NNS	I-NP
O	259	261	of	of	IN	B-PP
O	262	266	this	this	DT	B-NP
O	267	280	micronutrient	micronutrient	NN	I-NP
O	280	281	.	.	.	O

O	282	283	A	A	DT	B-NP
O	284	288	wide	wide	JJ	I-NP
O	289	294	range	range	NN	I-NP
O	295	297	of	of	IN	B-PP
O	298	305	binding	binding	NN	B-NP
O	306	307	(	(	(	O
O	307	308	5	5	CD	B-NP
O	308	309	.	.	.	O
O	309	310	9	9	CD	B-NP
O	311	313	to	to	TO	I-NP
O	314	317	130	130	CD	I-NP
O	318	323	pmole	pmole	NN	I-NP
O	323	324	/	/	SYM	B-NP
O	324	326	ml	ml	NN	I-NP
B-Organism_substance	327	333	plasma	plasma	NN	I-NP
O	333	334	)	)	)	O
O	335	338	was	be	VBD	B-VP
O	339	347	observed	observe	VBN	I-VP
O	347	348	,	,	,	O
O	349	352	and	and	CC	O
O	353	364	significant	significant	JJ	B-NP
O	365	375	elevations	elevation	NNS	I-NP
O	376	380	were	be	VBD	B-VP
O	381	386	found	find	VBN	I-VP
O	387	390	for	for	IN	B-PP
O	391	399	patients	patient	NNS	B-NP
O	400	406	having	have	VBG	B-VP
B-Cancer	407	413	breast	breast	NN	B-NP
I-Cancer	414	420	cancer	cancer	NN	I-NP
O	421	422	(	(	(	O
O	422	424	21	21	CD	B-NP
O	424	425	.	.	.	O
O	425	426	2	2	CD	B-NP
O	427	428	+	+	SYM	O
O	428	429	/	/	SYM	B-NP
O	429	430	-	-	SYM	B-NP
O	431	432	1	1	CD	I-NP
O	432	433	.	.	.	I-NP
O	433	434	9	9	CD	I-NP
O	434	435	,	,	,	O
O	436	437	P	P	NN	B-NP
O	438	442	less	less	JJR	B-NP
O	443	447	than	than	IN	I-NP
O	448	449	0	0	CD	I-NP
O	449	450	.	.	.	I-NP
O	450	452	05	05	CD	I-NP
O	452	453	)	)	)	O
O	454	457	and	and	CC	O
B-Cancer	458	466	melanoma	melanoma	NN	B-NP
O	467	468	(	(	(	O
O	468	470	25	25	CD	B-NP
O	470	471	.	.	.	I-NP
O	471	472	7	7	CD	I-NP
O	473	474	+	+	SYM	O
O	474	475	/	/	SYM	B-NP
O	475	476	-	-	SYM	B-NP
O	477	478	1	1	CD	I-NP
O	478	479	.	.	.	I-NP
O	479	480	9	9	CD	I-NP
O	480	481	,	,	,	O
O	482	483	P	P	NN	B-NP
O	484	488	less	less	JJR	B-NP
O	489	493	than	than	IN	I-NP
O	494	495	0	0	CD	I-NP
O	495	496	.	.	.	I-NP
O	496	499	001	001	CD	I-NP
O	499	500	)	)	)	O
O	501	509	compared	compare	VBN	B-VP
O	510	512	to	to	TO	B-PP
O	513	521	controls	control	NNS	B-NP
O	522	523	(	(	(	O
O	523	525	15	15	CD	B-NP
O	525	526	.	.	.	I-NP
O	526	527	5	5	CD	I-NP
O	528	529	+	+	SYM	B-NP
O	529	530	/	/	SYM	B-VP
O	530	531	-	-	SYM	B-NP
O	532	533	1	1	CD	I-NP
O	533	534	.	.	.	I-NP
O	534	535	9	9	CD	I-NP
O	535	536	)	)	)	O
O	536	537	.	.	.	O

O	538	541	The	The	DT	B-NP
O	542	550	proteins	protein	NNS	I-NP
O	551	562	responsible	responsible	JJ	B-ADJP
O	563	566	for	for	IN	B-PP
O	567	568	a	a	DT	B-NP
O	569	577	majority	majority	NN	I-NP
O	578	580	of	of	IN	B-PP
O	581	584	the	the	DT	B-NP
O	585	591	higher	high	JJR	I-NP
O	592	599	binding	binding	NN	I-NP
O	600	604	were	be	VBD	B-VP
O	605	615	identified	identify	VBN	I-VP
O	616	618	as	as	IN	B-PP
O	619	634	immunoglobulins	immunoglobulin	NNS	B-NP
O	634	635	,	,	,	O
O	636	641	based	base	VBN	B-VP
O	642	644	on	on	IN	B-PP
O	645	650	their	their	PRP$	B-NP
O	651	658	elution	elution	NN	I-NP
O	659	663	from	from	IN	B-PP
O	664	667	gel	gel	NN	B-NP
O	668	678	filtration	filtration	NN	I-NP
O	679	686	columns	column	NNS	I-NP
O	687	690	and	and	CC	O
O	691	694	the	the	DT	B-NP
O	695	702	removal	removal	NN	I-NP
O	703	705	of	of	IN	B-PP
O	706	708	57	57	CD	B-NP
O	708	709	-	-	HYPH	I-NP
O	709	711	88	88	CD	I-NP
O	711	712	%	%	NN	I-NP
O	713	715	of	of	IN	B-PP
O	716	719	the	the	DT	B-NP
O	720	723	non	non	AFX	I-NP
O	723	724	-	-	HYPH	I-NP
O	724	731	albumin	albumin	NN	I-NP
O	732	739	binding	binding	NN	I-NP
O	740	742	by	by	IN	B-PP
O	743	751	treating	treat	VBG	B-VP
O	752	754	of	of	IN	B-PP
B-Organism_substance	755	761	plasma	plasma	NN	B-NP
O	762	766	with	with	IN	B-PP
O	767	774	Protein	Protein	NN	B-NP
O	775	776	A	A	NN	I-NP
O	776	777	-	-	HYPH	I-NP
O	777	784	agarose	agarose	NN	I-NP
O	784	785	.	.	.	O

O	786	789	The	The	DT	B-NP
O	790	797	binding	binding	NN	I-NP
O	798	801	was	be	VBD	B-VP
O	802	806	only	only	RB	I-VP
O	807	813	weakly	weakly	RB	I-VP
O	814	821	related	relate	VBN	I-VP
O	822	824	to	to	TO	B-PP
O	825	828	the	the	DT	B-NP
O	829	834	total	total	JJ	I-NP
O	835	848	concentration	concentration	NN	I-NP
O	849	851	of	of	IN	B-PP
O	852	867	immunoglobulins	immunoglobulin	NNS	B-NP
O	868	869	(	(	(	O
O	869	870	r	r	NN	B-NP
O	871	872	=	=	SYM	B-VP
O	873	874	0	0	CD	B-NP
O	874	875	.	.	.	I-NP
O	875	877	11	11	CD	I-NP
O	878	880	by	by	IN	B-PP
O	881	887	linear	linear	JJ	B-NP
O	888	898	regression	regression	NN	I-NP
O	899	907	analysis	analysis	NN	I-NP
O	907	908	)	)	)	O
O	908	909	,	,	,	O
O	910	917	however	however	RB	B-ADVP
O	917	918	,	,	,	O
O	919	922	and	and	CC	O
O	923	925	is	be	VBZ	B-VP
O	926	936	apparently	apparently	RB	B-ADVP
O	937	940	due	due	JJ	B-ADJP
O	941	943	to	to	TO	B-PP
O	944	945	a	a	DT	B-NP
O	946	954	subclass	subclass	NN	I-NP
O	955	959	that	that	WDT	B-NP
O	960	962	is	be	VBZ	B-VP
O	963	971	elevated	elevate	VBN	I-VP
O	972	974	in	in	IN	B-PP
O	975	979	some	some	DT	B-NP
O	980	985	types	type	NNS	I-NP
O	986	988	of	of	IN	B-PP
B-Cancer	989	995	cancer	cancer	NN	B-NP
O	995	996	.	.	.	O

O	997	1005	Elevated	Elevated	JJ	B-NP
O	1006	1012	levels	level	NNS	I-NP
O	1013	1015	of	of	IN	B-PP
O	1016	1021	these	these	DT	B-NP
O	1022	1037	immunoglobulins	immunoglobulin	NNS	I-NP
O	1038	1041	may	may	MD	B-VP
O	1042	1052	contribute	contribute	VB	I-VP
O	1053	1055	to	to	TO	B-PP
O	1056	1059	the	the	DT	B-NP
O	1060	1065	lower	low	JJR	I-NP
B-Organism_substance	1066	1073	urinary	urinary	JJ	I-NP
O	1074	1080	levels	level	NNS	I-NP
O	1081	1084	and	and	CC	O
O	1085	1094	clearance	clearance	NN	B-NP
O	1095	1097	of	of	IN	B-PP
O	1098	1108	riboflavin	riboflavin	NN	B-NP
O	1109	1111	in	in	IN	B-PP
B-Cancer	1112	1118	cancer	cancer	NN	B-NP
O	1118	1119	.	.	.	O

